Evan Seigerman, BMO, joins ‘Fast Money’ to talk the latest oral obesity treatment data out of Eli Lilly.
Source link
Trending
- Ukraine reportedly agrees to peace proposal
- Dan Ives’ top tech picks into year-end
- Consumer confidence hits lowest point since April as job worries grow
- Stocks making the biggest moves premarket: KSS, NVDA, DKS, SYM
- An inside look at his analysis showing AI is a bubble
- Multifamily housing leads in October
- Private payroll losses accelerated in the past four weeks, ADP reports
- Abercrombie & Fitch (ANF) earnings Q3 2025
Eli Lilly's oral obesity treatment efficacy falls short of expectations, says BMO's Evan Seigerman
